BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.“Worldwide, approximately 15 to 20 million people are infected with delta hepatitis, and up to 80% of those patients may develop cirrhosis within 5 to 10 years,” Christopher Koh, MD, MHSc, FAASLD, from National Institutes of Health in Maryland, said during his presentation. “Patients with delta hepatitis are at aRead More